AI Article Synopsis
- Idiopathic pulmonary fibrosis (IPF) is a serious lung disease that leads to lung damage and has a poor prognosis, highlighting the need for new treatment options.
- Recent studies suggest that key cellular players in IPF are alveolar epithelial type II cells and fibroblasts, although the exact processes are still being researched.
- Platelet-derived growth factor (PDGF) is identified as an important molecule in IPF progression, as it promotes fibroblast growth and migration, making it a potential target for therapy.
Article Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal lung disease characterized by the proliferation of fibroblasts and deposition of extracellular matrix. Since the prognosis of IPF is still poor, novel therapeutic modalities are strongly required. For this reason, to find molecular target for therapy of IPF is of much importance. The recent understanding of pathogenesis in IPF indicates the critical role of alveolar epithelial type II cells (AECII) and fibroblasts. Although the detailed mechanisms involved in IPF is still unclear, various profibrotic mediators which are produced by the injured AECII are thought to play a role in the progression of pulmonary fibrosis via stimulating fibroblasts. Among them, platelet-derived growth factor (PDGF) is one of critical growth factors by stimulating the proliferation and migration of fibroblasts. In this review, we discuss the role of PDGF in pulmonary fibrosis and the possibility as a therapeutic target for IPF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2152/jmi.60.175 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!